Abstract
Nizatidine (Axid) is the newest of four histamine receptor antagonists approved by the Food and Drug Administration for treatment of duodenal ulcer and maintenance therapy. It is as effective as the other histamine blockers in healing active duodenal ulcers and in the prevention of relapse. Nizatidine is comparable in price to cimetidine (Tagamet). Nizatidine does not interfere with the hepatic metabolism of other drugs. No significant central nervous system side effects have been reported. It is safe to use in elderly patients or in patients with renal insufficiency. The dosage, however, should be decreased when renal function is impaired.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
